Literature DB >> 18055761

Identification of the first synthetic steroidogenic factor 1 inverse agonists: pharmacological modulation of steroidogenic enzymes.

Andria L Del Tredici1, Carsten B Andersen, Erika A Currier, Steven R Ohrmund, Luke C Fairbain, Birgitte W Lund, Norman Nash, Roger Olsson, Fabrice Piu.   

Abstract

Steroidogenic factor SF-1, a constitutively active nuclear hormone receptor, is essential to the development of adrenal and gonadal glands and acts as a shaping factor of sexual determination and differentiation. Its effects are exerted primarily through the control of the synthesis of steroid hormones. The functional cell-based assay Receptor Selection and Amplification Technology (R-SAT) was used to identify potent and selective SF-1 inverse agonists through the screening of a chemical library of drug-like small-molecule entities. Among them, 4-(heptyloxy)phenol (AC-45594), a prototype inverse agonist lead, was used to show that SF-1 constitutive activity can be pharmacologically modulated by a synthetic ligand. In a physiological system of endocrine function, the expression of several reported SF-1 target genes, including SF-1 itself, was inhibited by treatment with AC-45594 and analogs. Thus, pharmacological modulation of SF-1 is critical to its function as an endocrine master regulator and has potentially important consequences to diseases in which SF-1 activity is critical.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055761     DOI: 10.1124/mol.107.040089

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

Review 1.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

2.  Synthesis of small molecule inhibitors of the orphan nuclear receptor steroidogenic factor-1 (NR5A1) based on isoquinolinone scaffolds.

Authors:  Joshua Roth; Franck Madoux; Peter Hodder; William R Roush
Journal:  Bioorg Med Chem Lett       Date:  2008-03-14       Impact factor: 2.823

3.  Endometrial Expression of Steroidogenic Factor 1 Promotes Cystic Glandular Morphogenesis.

Authors:  Yasmin M Vasquez; San-Pin Wu; Matthew L Anderson; Shannon M Hawkins; Chad J Creighton; Madhumita Ray; Sophia Y Tsai; Ming-Jer Tsai; John P Lydon; Francesco J DeMayo
Journal:  Mol Endocrinol       Date:  2016-03-28

4.  Therapy of adrenocortical cancer: present and future.

Authors:  Daniela F Maluf; Brás H de Oliveira; Enzo Lalli
Journal:  Am J Cancer Res       Date:  2010-12-07       Impact factor: 6.166

Review 5.  Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease.

Authors:  Bernard P Schimmer; Perrin C White
Journal:  Mol Endocrinol       Date:  2010-03-04

Review 6.  Steroidogenic factor-1 (SF-1, Ad4BP, NR5A1) and disorders of testis development.

Authors:  L Lin; J C Achermann
Journal:  Sex Dev       Date:  2008-11-05       Impact factor: 1.824

7.  SF-1 deficiency causes lipid accumulation in Leydig cells via suppression of STAR and CYP11A1.

Authors:  Megumi Hatano; Toshiro Migita; Tomokazu Ohishi; Yuichi Shima; Yoshihiro Ogawa; Ken-Ichirou Morohashi; Yukihiro Hasegawa; Futoshi Shibasaki
Journal:  Endocrine       Date:  2016-07-25       Impact factor: 3.633

Review 8.  Phospholipid--driven gene regulation.

Authors:  Paul M Musille; Jeffrey A Kohn; Eric A Ortlund
Journal:  FEBS Lett       Date:  2013-01-16       Impact factor: 4.124

9.  Potent, selective and cell penetrant inhibitors of SF-1 by functional ultra-high-throughput screening.

Authors:  Franck Madoux; Xiaolin Li; Peter Chase; Gina Zastrow; Michael D Cameron; Juliana J Conkright; Patrick R Griffin; Scott Thacher; Peter Hodder
Journal:  Mol Pharmacol       Date:  2008-03-11       Impact factor: 4.436

10.  Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists.

Authors:  Mabrouka Doghman; Julie Cazareth; Dominique Douguet; Franck Madoux; Peter Hodder; Enzo Lalli
Journal:  J Clin Endocrinol Metab       Date:  2009-03-24       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.